Conditions: Non-Small Cell Lung Cancer
Keywords: Nonsmall Cell Lung Cancer NSCLC Non-Small-Cell Lung Carcinoma Carcinoma, Non-Small Cell Lung KW-0761 Mogamulizumab
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 13
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety of mogamulizumab in combination with docetaxel in adult subjects with previously treated locally advanced or metastatic non-small cell lung cancer.

Detailed description:

Arms:
arm 1: Mogamulizumab will be given as monotherapy in a 4-week run-in period. Subjects will then receive up to 6 cycles of mogamulizumab in combination with docetaxel at appropriate intervals.

Subjects may then continue to receive mogamulizumab, at the same dose administered in Cycle 1, once every 3 weeks as monotherapy.

Interventions: intervention 1: mogamulizumab intervention 2: Docetaxel
Intervention descriptions: intervention 1: Mogamulizumab will be administered by IV infusion. intervention 2: Docetaxel will be administered by IV infusion.

Protocol document: